ErkutHasanBorazanciMDMS

Cancer Genetics/Cancer Risk Assessment, Gastrointestinal Cancer, Hematologic Oncology

Physician

Overview of Dr. Borazanci

Dr. Erkut Borazanci is an oncologist in Scottsdale, AZ and is affiliated with multiple hospitals in the area, including HonorHealth Scottsdale Shea Medical Center, HonorHealth Scottsdale Osborn Medical Center, HonorHealth Deer Valley Medical Center, and HonorHealth Scottsdale Thompson Peak Medical Center. He received his medical degree from LSU School of Medicine in Shreveport and has been in practice 9 years. He is one of 35 doctors at HonorHealth Scottsdale Osborn Medical Center and one of 53 doctors at HonorHealth Scottsdale Shea Medical Center who specialize in Oncology. He has more than 90 publications and over 500 citings.

Office
10510 N 92nd Street Suite 200
Scottsdale, AZ 85258
Book by Phone+1(480) 571-2196
Is this information wrong?

Education & Training

LSU School of Medicine in ShreveportClass of 2008
Louisiana State University Health Sciences Center. ShreveportMS, Biochemistry and Molecular Biology, 2004
Louisiana State UniversityBS, Microbiology, 2001

Certifications & Licensure

AZ State Medical License 2013 - 2025
LA State Medical License 2010 - 2014
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Physician Leadership Award: Citizenship and Community Service. HonorHealth, 2016
CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

Clinical Trials

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Start of enrollment: 2014 Sep 01
Completed
Phase 1
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies Start of enrollment: 2016 Jan 01
Recruiting
Phase 1
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer Start of enrollment: 2016 Jun 15
Completed
Phase 1
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Start of enrollment: 2016 Apr 01
Active, not recruiting
Phase 2
Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer Start of enrollment: 2016 May 04
Completed
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) Start of enrollment: 2016 Sep 01
Completed
Phase 2
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors Start of enrollment: 2017 Jun 09
Completed
Phase 1
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer Start of enrollment: 2017 Jun 22
Completed
Phase 1, Phase 2
A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer Start of enrollment: 2017 Apr 10
Completed
Phase 2
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Start of enrollment: 2017 May 23
Active, not recruiting
Phase 2
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) Start of enrollment: 2018 Jan 31
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic...
Teresa Macarulla, Patrick M Peterson, Matteo Ceccarelli, Uwe Pelzer, Faithlore P Gardner, Zev A Wainberg, Christos Fountzilas, Nathan Bahary, Mark S Womack, Ignacio Ga...> ;Cancers. 2024 Mar 28
First-in-Human Phase I Study of Minnelide in Patients With Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity.
Saluja, A., Korn, R., Von Hoff, D., Greeno, E., Borazanci, E., Gockerman, J., Velagapudi, M.> ;The Oncologist. 2024 Feb 2
Choroidal metastasis of pancreatic adenocarcinoma: case report.
Jahnavi Shriram, Robert Stoltz, Erkut Borazanci> ;AME Case Reports. 2024 Jan 1
2 citations
A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma.
Caiming Xu, Eunsung Jun, Yoshinaga Okugawa, Yuji Toiyama, Erkut Borazanci, John Bolton, Akinobu Taketomi, Song Cheol Kim, Dong Shang, Daniel Von Hoff, Guixin Zhang, Aj...> ;Gastroenterology. 2024 Jan 1
2 citations
A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer.
Corina E Antal, Tae Gyu Oh, Stefan Aigner, En-Ching Luo, Brian A Yee, Tania Campos, Hervé Tiriac, Katherine L Rothamel, Zhang Cheng, Henry Jiao, Allen Wang, Nasun Hah,...> ;Nature Communications. 2023 Sep 6
2 citations
A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report.
Margaret Y Han, Erkut Borazanci> ;Journal of Gastrointestinal Oncology. 2023 Feb 28
1 citations
Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies.
Margaret Y Han, Erkut H Borazanci> ;Frontiers in Oncology. 2023 Jan 1
1 citations
A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas.
Manuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim, Wells A Messersmith, Ignacio Garrido-Laguna, Erkut Borazanci, Andrew M Lowy, Laura Medina Rodriguez, Daniel Lahe...> ;Cancer Research Communications. 2022 Nov 1
27 citations
An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
Kota Nakamura, Zhongxu Zhu, Souvick Roy, Eunsung Jun, Haiyong Han, Ruben M Munoz, Satoshi Nishiwada, Geeta Sharma, Derek Cridebring, Frederic Zenhausern, Seungchan Kim...> ;Gastroenterology. 2022 Nov 1
1 citations
Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib.
Gehan Botrus, Denise Roe, Gayle S Jameson, Pedro Luiz Serrano Uson Junior, Ronald Lee Korn, Lana Caldwell, Taylor Bargenquast, Max Miller, Erkut Hasan Borazanci> ;Biomedicines. 2022 Oct 26
Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
Kevin Drenner, Gargi D Basu, Laurie J Goodman, Audrey A Ozols, Janine R LoBello, Thomas Royce, Michael S Gordon, Erkut H Borazanci, Margaux A Steinbach, Jeffrey Trent,...> ;Oncotarget. 2022 Oct 20
2 citations
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINA...
Hani Babiker, Erkut Borazanci, Vivek Subbiah, Sanjiv Agarwala, Alain Algazi, Jacob Schachter, Michael Lotem, Corinne Maurice-Dror, Daniel Hendler, Shah Rahimian, Hans ...> ;Clinical Cancer Research. 2022 Dec 1
6 citations
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
Pamela N Munster, Andrew E Greenstein, Gini F Fleming, Erkut Borazanci, Manish R Sharma, Joseph M Custodio, Iulia Cristina Tudor, Hristina I Pashova, Stacie Peacock Sh...> ;Clinical Cancer Research. 2022 Aug 2
Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Nature. 2021 Nov 30
21 citations
EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers.
Raju Kandimalla, Jianfeng Xu, Alexander Link, Takatoshi Matsuyama, Kensuke Yamamura, M. Iqbal Parker, Hiroyuki Uetake, Francesc Balaguer, Erkut Borazanci, Susan Tsai, ...> ;Clinical Cancer Research. 2021 Sep 20
The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
Kevin Drenner, Gargi D. Basu, Laurie J. Goodman, Audrey A. Ozols, Janine LoBello, Thomas Royce, Michael S. Gordon, Erkut Borazanci, Margaux Steinbach, Jeffrey M. Trent...> ;Oncotarget. 2021 Aug 31
35 citations
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Bruno Bockorny, Teresa Macarulla, Valerya Semenisty, Erkut Borazanci, Jaime Feliu, Mariano Ponz-Sarvise, David Gutierrez Abad, Paul E. Oberstein, Angela Tatiana Alista...> ;Clinical Cancer Research. 2021 Sep 15
92 citations
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced...
Gerald Steven Falchook, Jeffrey R. Infante, Hendrik-Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham P...> ;Eclinicalmedicine. 2021 Mar 30
87 citations
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Davide Melisi, Do Youn Oh, Antoine Hollebecque, Emiliano Calvo, Anna M. Varghese, Erkut Borazanci, Teresa Macarulla, Valeria Merz, Camilla Zecchetto, Yumin Zhao, Iveli...> ;Journal for Immunotherapy of Cancer. 2021 Mar 1
2 citations
Role of 3D Volumetric and Perfusion Imaging for Detecting Early Changes in Pancreatic Adenocarcinoma.
Syed Rahmanuddin, Ronald L. Korn, Derek Cridebring, Erkut Borazanci, Jordyn Brase, William Boswell, Asma Jamil, Wenli Cai, Aqsa Sabir, Pejman Motarjem, Eugene J. Koay,...> ;Frontiers in Oncology. 2021 Sep 8
5 citations
A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Erkut Borazanci, Michael J. Pishvaian, John Nemunaitis, Colin D. Weekes, Julie Huang, Nishanthan Rajakumaraswamy> ;The Oncologist. 2020 Nov 1
109 citations
Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions
Wei Lin, Pawan Noel, Erkut Borazanci, Jeeyun Lee, Albert Amini, In Woong Han, Jin Seok Heo, Gayle S. Jameson, Cory Fraser, Margaux Steinbach, Yanghee Woo, Yuman Fong, ...> ;Genome Medicine. 2020 Sep 29
49 citations
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.
Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw, Ryohei Katayama, Yuki Shimizu, Viola W. Zhu, Thomas Yang Sun, Heather A. Wakelee, Russell Madison, Alexa B. S...> ;Clinical Cancer Research. 2020 Sep 15
267 citations
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny, Valerya Semenisty, Teresa Macarulla, Erkut Borazanci, Brian M. Wolpin, Salomon M. Stemmer, Talia Golan, Ravit Geva, Mitesh J. Borad, Katrina S. Pederse...> ;Nature Medicine. 2020 Jun 1
18 citations
A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma
Marc T. Roth, Dana Backlund Cardin, Erkut Borazanci, Margaux Steinbach, Vincent J. Picozzi, Alexander Rosemury, Raymond C. Wadlow, Jordan Berlin> ;The Oncologist. 2020 Oct 1
Join now to see all

Journal Articles

Ask ACCC’s Community Resource Centers: Pancreatic adenocarcinoma
Borazanci, E, Oncology, 1/1/2014

Abstracts/Posters

Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640
Emma Jane Dean, Gerald Steven Falchook, Manish R. Patel, Andrew Jacob Brenner, Jeffrey R. Infante, Hendrik-Tobias Arkenau, Erkut Hasan Borazanci, Juanita Suzanne Lopez..., J Clin Oncol, 1/1/2016
Phase 1b study of aldoxorubicin + gemcitabine in metastatic solid tumors.
Kamalesh Kumar Sankhala, Shanta Chawla, Victoria S. Chua, Jasgit C. Sachdev, Erkut Hasan Borazanci, Kelli Sung, Monica M. Mita, Alain C. Mita, Brenda Laabs, Scott Wiel..., J Clin Oncol, 1/1/2016
First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumors.
Kyriakos P. Papadopoulos, Erkut Borazanci, Daniel Von Hoff, Leena Gandhi, Amita Patnaik, Masaya Tachibana, Hamim Zahir, Roohi Gajee, Terri Goldberg, Giorgio Senaldi, S..., AACR, New Orleans, LA, 1/1/2016
A retrospective analysis assessing effects of cytotoxic versus cytostatic agents on body mass, nutritional parameters, and performance status in patients with exocrine...
Schwerkoske JP, Borazanci E, Schroeder K, Zhang L, Jameson GS, Schaffer JR, Nieves JA, and Von Hoff DD., GI ASCO 2015 Meeting. J Clin Oncol, 1/1/2015
Adenosquamous Carcinoma of the Pancreas: molecular characterization of 23 patients along with a literature review. Submitted for publication.
Borazanci E, Millis S, Korn R, Han H, Whatcott CJ, Gatalica Z, Barrett MT, D Cridebring D, and Von Hoff MD., World Journal of Gastronintestinal Oncology, 1/1/2015
Nab-paclitaxel and Gemcitabine for the treatment of patients with metastatic pancreatic cancer.
Borazanci E and Von Hoff DD., Expert Review of Gastroenterology & Hepatology, 1/1/2014
Potential actionable targets in appendiceal cancer detected by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), and mutational analysis. Poster pr...
Borazanci E, Millis SZ, Feldman RA, Ghazalpour A, Von Hoff DD, Ramanathan RK., ASCO Meeting. J Clin Oncol, 1/1/2014
Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer.
Borazanci E, Schroeder K, Jameson G, Ramanathan R, and Von Hoff DD, GI ASCO 2014 Meeting. J Clin Oncol, 1/1/2014
Detection of potential actionable targets in appendiceal cancer detected by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), and mutational analysis
Borazanci E, Kimbrough J, Sachdev JC, Millis SZ, Ejadi S, Burnett K, Ratliff S, Von Hoff DD, Ramanathan RK, GI ASCO 2014 Meeting. J Clin Oncol, 1/1/2014
Association of core-binding factor Beta with the malignant phenotype of prostate and ovarian cancer cells.
Davis JN, Rogers D, Adams L, Yong T, Jung JS, Cheng B, Fennell K, Borazanci E, Moustafa YW, Sun A, Shi R, Glass J, Mathis JM, Williams BJ, Meyers S., J Cell Physiol., 1/1/2010
RUNX Expression profiling abstract.
Piper VG, LSUHSC-S Barlow Symposium, Shreveport, LA, 1/1/2004
Phase I Dose Escalation and Pharmokinetic Study of 14-O-phosphonooxymethyltriptolide.
Edward Greeno, Erkut Borazanci, Jon Gockerman, Ronald Korn, Ashok Saluja, Daniel Von Hoff., AACR 2015 Annual Meeting, Philadelphia, PA, 1/18/2015
Evaluating high risk BI-RADS 4 mammographic lesions: a pilot trial of textural analysis (TA) as a supplement to digital mammography (DM)
Melissa R Gordon, Erkut Borazanci, Daniel D Maki, and Ronald Korn., AACR 2015 Annual Meeting, Philadelphia, PA, 1/18/2015
High complete and partial response rate in a phase Ib pilot trial with albumin-bound paclitaxel and gemcitabine plus cisplatin in patients with advanced pancreatic cancer
Jameson GS, Borazanci E, Poplin E, Barrett MT, Crowley J, Rosenthal A, Stoll -D’Astice A, Ansaldo K, Boone S, Lebron L, Ramanathan RK, Korn R, Von Hoff DD., AACR 2015 Annual Meeting, Philadelphia, PA, 1/18/2015
Prognosis of baseline absolute lymphocyte count (ALC) and neutrophil to lymphocyte ratio (NLR) in patients with pancreatic adenocarcinoma.
Sachin Pai, Kartik Anand, Erkut Borazanci, Runhua Shi, Syed H Jafri, and Glenn Mills., Louisiana Cancer Research Consortium Scientific Retreat, New Orleans, LA, 1/10/2015
RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region.
Fowler, M, Borazanci E, McGhee L, Pylant SW, Williams BJ, Glass J, Davis JN, Meyers S., J Cell Biochem, 1/1./2006
Improving Pancreatic Cancer Risk Prediction through Early Detection.
Courtney Snyder, Susan G. Haag, Nickie Adams, Jade Hess, Breann Paskett, and Erkut H. Borazanci., AACR Conference: Improving Cancer Risk Prediction for Prevention and Early Detection, 1/16/2016
Ibrutinib + durvalumab (MEDI4736) in patients (pts) with relapsed or refractory (R/R) pancreatic adenocarcinoma (PAC): A phase Ib/II multicenter study.
Erkut Hasan Borazanci, David S. Hong, Martin Gutierrez, Drew W. Rasco, Tony R. Reid, Michael H. Veeder, Ahmed Tawashi, Jennifer Lin, Isaiah W. Dimery., J Clin Oncol, Gastrointestinal Cancers Symposium, San Francisco, 1/21/2016
Phase I dose escalation and pharmokinetic study of a modified schedule of 14-o-phosphonooxymethyltriptolide.
Edward Greeno, Erkut Hasan Borazanci, Jon P. Gockerman, Ronald Lee Korn, Ashok Saluja, Daniel D. VonHof., J Clin Oncol, Gastrointestinal Cancers Symposium, San Francisco, 1/21/2016
A First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 Results of Dose Escalation in Mono and Combination and Evidence of Prelimina...
A. Brenner, J. Infante, M. Patel, HT. Arkenau, M. Voskoboynik , E. Borazanci, G. Falchook , L.R. Molife , S. Pant , E. Dean ,L. Pelosof , S. Jones, C. Rubino , W. McCu..., AACR-NCI-EORTC 2015 meeting, 1/6./2015
Ibrutinib in combination with durvalumab (MEDI4736) in patients with relapsed or refractory HER2-positive or triple-negative breast cancer: A phase 1b/2 multicenter st...
Drew W. Rasco, Erkut Borazanci, Martin Guiterrez, David Hong, Ahmed Tawash, Jennifer Lin, Isaiah W. Dimery, Mark Fosdale, AACR Advances in Breast Cancer Research, Bellevue, WA
Prognosis of baseline absolute lymphocyte count (ALC) and neutrophil to lymphocyte ratio (NLR) in patients with pancreatic adenocarcinoma.
Kartik Anand, Sachin Pai, Erkut Borazanci, Runhua Shi, Syed H Jafri, and Glenn Mills., AACR 2015 Annual Meeting, Philadelphia, PA, 1/18/2015
Join now to see all

Lectures

A phase I dose-escalation and immune biomarker study of intravenous FF-10832, liposomal gemcitabine, in patients with advanced solid tumors.
2019 ASCO Annual Meeting - 6/1/2019
A Pilot, Phase II study in patients treated with MM-398, nanoliposomal irinotecan (nal-IRI) using Ferumoxytol (FMX) contrast MRI as a biomarker to predict patient resp...
1/1/2014
Foreign Body Ingestion-presented to LSUHSC-S pediatric students and pediatric staff.
Shreveport, LA - 1/1/2007
Thesis defense, RUNX Expression Profiling in Human Cell Lines and Tissue
LSUHSC-S Department of Biochemistry and Molecular Biology. Shreveport, LA - 1/1/2004
Vitamin D and Pancreas Cancer
Scottsdale, AZ - 1/19/2016
Pancreatic Cancer.
University of Arizona, Phoenix Campus, Phoenix, AZ. - 1/7./2016
The Molecular Medicine Initiative: Pancreatic Cancer.
1/23/2016
Pancreatic Cancer: Where we are at and where we are going.
1/15/2015
The Biology of Cancer lecture series
HonorHealth Research Institute. - 1/3./2015
A case of Adenosquamous pancreatic cancer.
Scottsdale, AZ. - 1/24/2015
Pancreatic Cancer: Disease Area Background
Chicago, IL - 1/17/2015
LifeLong Learning Program
PebbleCreek. Goodyear, AZ - 1/20/2015
Utilizing Cancer Pathways for Drug Development.
LSU Health Shreveport, Shreveport, LA - 1/13/2015
Review of RECIST 1.1.
Scottsdale, AZ. - 1/23/2014
Cancer Genomics.
Shreveport, LA. - 1/11/2013
Treating Advanced Pancreatic Cancer: Finding the Blueprint for Success
Shreveport, LA. - 1/29/2012
Cervical Neoplasia in patients with Systemic Lupus Erythematosus.
Shreveport, LA. - 1/22/2011
Bisphosphonates and Atypical Fractures
Shreveport, LA - 1/21/2010
Dyslipidemia
Shreveport, LA. - 1/1./2010
Cirrhosis secondary to NASH
Shreveport, LA - 1/15/2010
Morbidity and Mortality Case presentation
Overton Brooks VA Medical Center Internal Medicine. Shreveport, LA - 1/22/2009
Vitamin D Deficiency
Shreveport, LA - 1/5./2008
Join now to see all

Other

Symptoms of Impending Gallbladder Perforation and Acute Cholecystitis in a Pancreatic Cancer Patient Masked by Celiac Plexus Block
Borazanci E, Luke Dreisbach L, and Ramanathan RK, Gastroenterology & Hepatology: Open Access
http://medcraveonline.com/GHOA/GHOA-02-00059.pdf
1/1/2015
Multiplatform profiling of rare pancreatic carcinoma subtypes to identify potential actionable targets.
Borazanci E, Millis SZ, Winkler J, Ramanathan RK, Von Hoff DD., ASCO Meeting. J Clin Oncol
1/1/2014
HonorHealth seeks patients for pancreatic cancer
Channel 4TV/CBS5
http://www.azfamily.com/story/32294178/honorhealth-seeks-patients-for-pancreatic-cancer-study
1/23/2016
Scottsdale-based study seeks answers on deadly pancreatic cancer.
AZ Republic
http://www.azcentral.com/story/news/local/scottsdale/2016/04/04/scottsdale-based-study-seeks-answers-deadly-pancreatic-cancer/80807292/
1/4./2016
Arizona Republic
Ask the Expert
http://www.azcentral.com/story/entertainment/life/health/2016/01/22/researchers-hope-develop-pancreatic-cancer-screening/79154224/?from=global&sessionKey=&autologin=
1/22/2016
Interview regarding the Stand Up to Cancer Grant
KJZZ
http://kjzz.org/content/218308/arizona-agencies-picked-international-pancreas-cancer-research-dream-team
1/12/2015
Interview regarding clinical trials and pancreatic cancer.
Local NPR KJZZ
http://kjzz.org/content/97425/clinical-trial-new-pancreatic-cancer-drugs-scottsdale
1/4./2015
Phoenix interview regarding clinical trials and pancreatic cancer
Channel 15
http://www.abc15.com/news/region-northeast-valley/scottsdale/arizona-cancer-clinical-trial-gives-scottsdale-man-a-second-chance-at-life
1/9./2015
Radio interview regarding clinical trials and pancreatic cancer.

http://ktar.com/22/1796022/Clinical-trial-leads-to-potential-miracle-for-Valley-cancer-patient-
1/5./2015
Interview with Jared Dillingham regarding clinical trials and pancreatic cancer
KTVK
http://www.azfamily.com/home/Stage-4-pancreatic-cancer-now-untraceable-in-Phoenix-man-287077571.html
1/29/2014
Interview with Jay Crandall regarding FDA approval of Cologuard

http://www.azfamily.com/news/health/New-Colon-Cancer-test-272634691.html
1/25/2014
Join now to see all

Press Mentions

Creating Method for Scoring Pancreatic Cancer Patients for SurgeryApril 7th, 2023
HonorHealth Researchers' New Therapy Changes NCCN Guidelines for Pancreatic CancerJune 21st, 2022
Pancreatic Cancer Trial Launched by TGen, HonorHealth, and SBIMarch 23rd, 2022
Join now to see all